General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option?
Because of its increasing incidence of hepatocellular carcinoma, it is now recognized as a worldwide health problem affecting mostly patients with chronic liver disease. Liver transplantation is the optimal therapy and achieves its best results in patients with small tumour burden. In an effort to prevent tumour progression and patient dropout from the transplant wait list, the concept and utilization of neo-adjuvant locoregional therapies have gained relevance in the past few years. Moreover, good and maintained response to therapy is now considered a surrogate of favourable tumour biology, therefore aiding the patient transplant selection process. Herein, we review the current role of neo-adjuvant therapies and revise concepts of tumour 'downstaging' or 'bridging therapy' in the setting of liver transplantation. In addition, we explore the debate of implementing locoregional therapy for patients with small tumours and short waiting times to liver transplantation.
Department of Liver Transplantation and Hepatobiliary Surgery, Cleveland Clinic, Cleveland, OH, USA.
Masato
M
Fujiki
Federico
F
Aucejo
Richard
R
Kim
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D019317:Evidence-Based Medicine; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D016031:Liver Transplantation; D020360:Neoadjuvant Therapy; D018579:Patient Selection; D016896:Treatment Outcome; D014850:Waiting Lists
D000970:Antineoplastic Agents